PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
47.85%
Revenue growth of 47.85% while CSIQ is flat. Bruce Berkowitz would check if a small edge can widen further.
40.78%
Gross profit growth of 40.78% while CSIQ is zero. Bruce Berkowitz would see if minimal improvements could expand further.
13.17%
EBIT growth of 13.17% while CSIQ is zero. Bruce Berkowitz would see if small gains can be scaled further.
13.17%
Operating income growth of 13.17% while CSIQ is zero. Bruce Berkowitz would see if this modest edge can become significant.
12.45%
Net income growth of 12.45% while CSIQ is zero. Bruce Berkowitz would see if small gains can accelerate into a larger gap.
82.61%
EPS growth of 82.61% while CSIQ is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
82.61%
Diluted EPS growth of 82.61% while CSIQ is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
403.26%
Share change of 403.26% while CSIQ is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
403.26%
Diluted share change of 403.26% while CSIQ is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
206.87%
OCF growth of 206.87% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
94.69%
FCF growth of 94.69% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.42%
Our R&D shrinks while CSIQ invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
22.39%
SG&A growth of 22.39% while CSIQ is zero. Bruce Berkowitz sees more spend on admin or marketing, expecting stronger top-line in return.